Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103168
Status:
COMPLETED
Last Update Posted:
2018-07-09
First Post:
2005-02-07
Brief Title:
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
Intermediate and High Risk Localized Completely Resected Gastrointestinal Stromal Tumors GIST Expressing KIT Receptor A Controlled Randomized Trial on Adjuvant Imatinib Mesylate Glivec Versus No Further Therapy After Complete Surgery
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth Giving imatinib mesylate after surgery may kill any remaining tumor cells It is not yet known whether imatinib mesylate is more effective than observation only in treating gastrointestinal stromal tumor
PURPOSE This randomized phase III trial is studying imatinib mesylate to see how well it works compared to observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor
PURPOSE This randomized phase III trial is studying imatinib mesylate to see how well it works compared to observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor
Detailed Description:
OBJECTIVES
Primary
Assess whether there is a difference in overall survival between intermediate and high-risk localized GIST patients undergoing complete surgery alone and those undergoing complete surgery plus adjuvant imatinib mesylate 400 mg daily for two years Secondary
Assess whether there is a difference in relapse-free survival and relapse-free interval between GIST undergoing complete surgery alone and those undergoing surgery adjuvant Imatinib mesylate 400 mg daily for two years
Determine the safety of this drug in these patients
OUTLINE This is a randomized open-label multicenter study Patients are stratified according to participating center risk category high vs intermediate tumor site gastric vs other and resection level R0 vs R1
Arm I Patients receive adjuvant oral imatinib mesylate once daily for 2 years in the absence of disease progression or unacceptable toxicity
Arm II Patients are observed without receiving further antitumoral therapy every 3 months for 2 years
After completion of study treatment patients in arm I are followed every 3 months for 2 years All patients are then followed every 4 months for 3 years and at least annually thereafter
PROJECTED ACCRUAL A total of 900 patients will be accrued for this study within 35 years
Primary
Assess whether there is a difference in overall survival between intermediate and high-risk localized GIST patients undergoing complete surgery alone and those undergoing complete surgery plus adjuvant imatinib mesylate 400 mg daily for two years Secondary
Assess whether there is a difference in relapse-free survival and relapse-free interval between GIST undergoing complete surgery alone and those undergoing surgery adjuvant Imatinib mesylate 400 mg daily for two years
Determine the safety of this drug in these patients
OUTLINE This is a randomized open-label multicenter study Patients are stratified according to participating center risk category high vs intermediate tumor site gastric vs other and resection level R0 vs R1
Arm I Patients receive adjuvant oral imatinib mesylate once daily for 2 years in the absence of disease progression or unacceptable toxicity
Arm II Patients are observed without receiving further antitumoral therapy every 3 months for 2 years
After completion of study treatment patients in arm I are followed every 3 months for 2 years All patients are then followed every 4 months for 3 years and at least annually thereafter
PROJECTED ACCRUAL A total of 900 patients will be accrued for this study within 35 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EORTC-62024 | None | None | None |
| ISG-62024 | None | None | None |
| FRE-FNCLCC-EORTC-62024 | None | None | None |
| GEIS-EORTC-62024 | None | None | None |
| 2004-001810-16 | EUDRACT_NUMBER | None | None |